Company Overview and News

64
Tuesday’s Vital Data: Bank of America, Canopy Growth Corp and Morgan Stanley

2018-10-16 investorplace
Editor’s Note: Vital Data is taking a hiatus Wednesday through Friday and will return on Monday, Oct. 22.
BAC GS JNJ WEED MS CGC

56
7 Best ETFs to Buy Now for Defensive Stocks

2018-10-16 investorplace
With seasonal volatility, rising interest rates, uncertainty over a tariff war with China and fast-approaching mid-term elections all on the minds of investors, the best ETFs to buy now are those that invest in defensive areas of the market.
ABT DUKH STZ.B PG D DUK STZ ABT GLD O87 JNJ KO CI PFE UNH NEE

14
Q3 Earnings Reports: MSFT, NFLX, GS, MS, UNH, JNJ

2018-10-16 zacks
If you’re a market participant looking to re-direct your focus away from international challenges like Saudi Arabia, North Korea, Russia, et. al., you’re in luck: Q3 earnings reports are hitting the tape fast and furious at this hour. We will take this opportunity to summarize a handful of them.
JNJ NFLX MSFT MS

13
Should Johnson & Johnson Be Getting More Out of Q3 Earnings?

2018-10-16 247wallst
Johnson & Johnson (NYSE: JNJ) reported its third-quarter financial results before the markets opened on Thursday. The company said that it had $2.05 in earnings per share (EPS) and $20.35 billion in revenue. That compared with consensus estimates of $2.03 in EPS and $20.05 billion in revenue, as well as the $1.90 per share and $19.65 billion posted in the same period of last year.
JNJ

18
Johnson & Johnson (JNJ) Surpasses Q3 Earnings and Revenue Estimates

2018-10-16 zacks
Johnson & Johnson (JNJ - Free Report) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.90 per share a year ago. These figures are adjusted for non-recurring items.
MBWM JNJ CTRL UNH

31
10 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targets And Dividends

2018-10-16 seekingalpha
October's top net gain "safer" Healthcare WallStar is AbbVie. Its projected 23% net gain was 2.3% better than Sanofi's, and 3.4% more than Grifol's result per analyst targets of 10/12/18.
AMGN GRFS GILD DGX MCK SNY MDT STE JNJ PRGO NVS ABBV ABBV

15
JNJ / Johnson & Johnson 8-K (Current Report)

2018-10-16 sec.gov - 2
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
JNJ

13
Can Johnson & Johnson Rally After Earnings?

2018-10-16 seekingalpha
Share prices in Johnson & Johnson have fallen to near-term lows, and investors are looking to the third-quarter earnings report for new signs of optimism.
JNJ

13
Can Johnson & Johnson Beat Earnings?

2018-10-16 seekingalpha
Share prices in Johnson & Johnson have fallen to near-term lows, and investors are looking to the third-quarter earnings report for new signs of optimism.
JNJ

56
7 Stocks to Buy and Hold Through Any Market Selloff

2018-10-15 investorplace - 1
Last week’s market collapse made headlines throughout the world. Even my professional associates who aren’t necessarily investment-savvy asked for my thoughts and guidance. After years of robust returns, the thought of a widespread correction is jarring. Nevertheless, you still want to keep your wits about you, as this is an ideal time to consider which stocks to buy.
AMZN ABX T PX JNJ XOM VZ INTC VZA ABX

73
5 Top Stock Trades for Tuesday: Trading Bank Earnings

2018-10-15 investorplace
A late-afternoon bounce in U.S. equities helped lift investors’ spirits, but doubts still linger as key indices hang near their 200-day moving averages and as tech continues to struggle ahead of earnings season. Here are our top stock trades to start the week.
BAC GS SCHW JPM JNJ ATVI

29
Getting Into The Weeds

2018-10-15 seekingalpha - 1
The changes that are underway closely mirror the process that alcohol went through after prohibition ended in the 1920s: liquor regained social acceptance and the product proliferated.
STZ.B ACBFF ITYBF TLRY APH WEED RLLRF GWP SMG IMBBY SHOP RRL CRON SF SFN STZ CGC HEIA QBC MFC ACB 0945 JNJ CBD MFC APHQF SFB IMBBF CNNRF

39
Can A Dividend Growth Portfolio Beat Index Funds?

2018-10-15 seekingalpha
I compare two index based funds to a DG portfolio I created for an article 2 years ago.
WFCNP LMT XOM OPRF WMT CL WFC GEC GE O CLGQY JNJ GNE MSFT

22
Healthcare Stocks: Rally In Jeopardy?

2018-10-15 seekingalpha
But recent declines in the SPDR Healthcare Select Sector Fund have called into question the validity of these trends, and forced many investors to consider taking profits at current levels.
JNJ ABBV ABBV

14
SPY: The Beginning Of The End? - Part 3

2018-10-15 seekingalpha
The bears look hungry but the broader picture suggests this is nothing more than a healthy pullback.
JNJ AAPL MS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to JNJ / Johnson & Johnson on message board site Silicon Investor.

JNJ-Super company, Super stock! JNJ-Super company, Super stock! JNJ-Super company, Super stock!
CUSIP: 478160104